World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Cited by in CrossRef

For:	Gao W, Li JW, Ye H, Zhang XZ, Liu JX, Cheng H. Real-world evidence on the efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori treatment in elderly patients. World J Gastroenterol 2025; 31(1): 101463 [PMID: 39777248 DOI: 10.3748/wjg.v31.i1.101463]
URL:	https://www.wjgnet.com/1007-9327/full/v31/i1/101463.htm

(150) (143) (0) (0) (0) (28) (8608) (7)

Number	Citing Articles
1	Xue Fan, Yanyan Shi, Yuan Li, Xiangchun Lin. Comparison of Vonoprazan and Low-Dose Amoxicillin Dual Therapy with Bismuth-Containing Quadruple Therapy for Naïve Helicobacter pylori Eradication: A Single-Center, Open-Label, Randomized Control Trial. Antibiotics 2025; 14(10) doi: 10.3390/antibiotics14100990
2	Ruyi Qi, Feng Zhou. Efficacy analysis of a bismuth-containing quadruple therapy with vonoprazan for Helicobacter pylori infection . Scandinavian Journal of Gastroenterology 2026; 61(4) doi: 10.1080/00365521.2026.2622659
3	Subeikshanan Venkatesan, Brandon Lucke-Wold. Mind the gut: Navigating the complex landscape of gastroprotection in neurosurgical patients. World Journal of Gastroenterology 2025; 31(8): 102959 doi: 10.3748/wjg.v31.i8.102959 Abstract(706) \| Core Tip(614) \| Full Article(HTML)(2852) \| Full Article (PDF)-409K(239) \| Full Article with Cover (PDF)-676K(203) \| Full Article (XML)-114K(135) \| Audio-1162K(33) \| Peer-Review Report-275K(130) \| Answering Reviewers-13K(119) \| Times Cited (17) \| Total Visits (6266) \| Open
4	Mubin Ozercan, Ahmed Tawheed, Alaa Ismail, Mohab Sherif Amer, Mohamed El-Kassas. Vonoprazan and proton pump inhibitors: Which is superior for <i>Helicobacter pylori</i> eradication?. World Journal of Gastroenterology 2025; 31(17): 103156 doi: 10.3748/wjg.v31.i17.103156 Abstract(465) \| Core Tip(558) \| Full Article(HTML)(7076) \| Full Article (PDF)-410K(333) \| Full Article with Cover (PDF)-1873K(192) \| Full Article (XML)-111K(114) \| Audio-156K(20) \| Peer-Review Report-217K(130) \| Answering Reviewers-59K(124) \| Times Cited (2) \| Total Visits (7894) \| Open
5	Jin‐Yan Zhang, Ji Li, Wei‐Feng Huang, Xiao‐Yi Lei, Yu‐Lin Huang, Gui‐Hua Xu, Dong Xu. Efficacy and Safety of Vonoprazan‐Based Dual, Triple, and Quadruple Therapies for Helicobacter pylori Eradication: A Randomized Controlled Trial. Helicobacter 2026; 31(2) doi: 10.1111/hel.70112
6	Sowmya Errabaka, Haritha Pasupulati, Satyanarayana SV Padi. PRAZANs or PCABs, Potassium Competitive Acid Blockers: A New Therapeutic Class in Acid-Related Diseases. International Journal of Health Sciences and Research 2026; doi: 10.52403/ijhsr.20260215
7	Tong Zhang, Tingxu Yang, Zhuoma Cailang, Zhihai He, Lili Ma, Yanhe Zheng, Xiaojuan Kang, Tingting Chen, Shufang Zhang, Sangmao Deji, Songyang Yao, Yongnai Zhuang, Dekui Zhang. Doxycycline plus vonoprazan for Helicobacter pylori eradication: A multicenter randomized noninferiority trial . Therapeutic Advances in Gastroenterology 2026; 19 doi: 10.1177/17562848261495724

Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.